BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 2020;8:304-20. [PMID: 32113575 DOI: 10.1016/S2213-2600(19)30480-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 106] [Article Influence: 48.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Liu T, Huang S, Qiu L, Luo F, Yin G, Xie Q. Screening value of lung ultrasound in connective tissue disease related interstitial lung disease. Heart & Lung 2023;57:110-116. [DOI: 10.1016/j.hrtlng.2022.09.011] [Reference Citation Analysis]
2 Li K, Wang Q, Lv Q, Guo K, Han L, Duan P, Deng Y, Bian H. Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model. BMC Complement Med Ther 2022;22:167. [DOI: 10.1186/s12906-022-03651-9] [Reference Citation Analysis]
3 Yang B, Rui H, Xue J, Liu J, Xiao H. The immune landscape in SSc-ILD and tow genes are potential risk factors for pulmonary fibrosis.. [DOI: 10.21203/rs.3.rs-2251740/v1] [Reference Citation Analysis]
4 El-adili F, Lui JK, Najem M, Farina G, Trojanowska M, Sam F, Bujor AM. Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther 2022;24:251. [DOI: 10.1186/s13075-022-02943-2] [Reference Citation Analysis]
5 Yakut H, Ozalevli S, Aktan R, Erez Y, Birlik M. Comparison of pulmonary function, respiratory symptoms, functional level, and health-related quality of life in patients with systemic sclerosis according to smoking status. Physiotherapy Theory and Practice 2022. [DOI: 10.1080/09593985.2022.2145176] [Reference Citation Analysis]
6 Mlakar L, Garrett SM, Watanabe T, Sanderson M, Nishimoto T, Heywood J, Helke KL, Pilewski JM, Herzog EL, Feghali-bostwick C. Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants. Biomedicines 2022;10:2861. [DOI: 10.3390/biomedicines10112861] [Reference Citation Analysis]
7 Chatterjee S, Perelas A, Yadav R, Kirby DF, Singh A. Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2022. [PMID: 36271064 DOI: 10.1007/s10067-022-06408-4] [Reference Citation Analysis]
8 Sezer A, Kayhan G, Gursoy TR, Eyuboglu TS, Percin FE. A homozygous missense variant in the WRN gene segregating in a family with progressive pulmonary failure with recurrent spontaneous pneumothorax and interstitial lung disease. Am J Med Genet A 2022. [PMID: 36214313 DOI: 10.1002/ajmg.a.62986] [Reference Citation Analysis]
9 Broens B, Duitman JW, Zwezerijnen GJC, Nossent EJ, van der Laken CJ, Voskuyl AE. Novel tracers for molecular imaging of interstitial lung disease: A state of the art review. Autoimmun Rev 2022;:103202. [PMID: 36150433 DOI: 10.1016/j.autrev.2022.103202] [Reference Citation Analysis]
10 Machhua S, Sharma SK, Kumar Y, Singh S, Anand S, Handa S, Minz RW. Detection of Epstein-Barr virus in systemic sclerosis patients: A molecular and serological based study. Int J Rheum Dis 2022. [PMID: 36102054 DOI: 10.1111/1756-185X.14440] [Reference Citation Analysis]
11 Wang N, Zhang Q, Sun W, Yang X, Huang H, Xu Z. Exome sequencing link mutation in RGPD4 with systemic sclerosis-associated interstitial lung disease and the low level of testosterone—an exploration study. Front Oncol 2022;12:956552. [DOI: 10.3389/fonc.2022.956552] [Reference Citation Analysis]
12 Juge P, Borie R, Debray M, Cazes A, Bancal C, Crestani B, Dieudé P. Dépistage des manifestations pulmonaires des connectivites. Revue du Rhumatisme Monographies 2022;89:252-259. [DOI: 10.1016/j.monrhu.2022.07.007] [Reference Citation Analysis]
13 Guarneri A, Perrone E, Bosello SL, D’agostino MA, Leccisotti L. The role of PET/CT in connective tissue disorders: systemic sclerosis, Sjögren's syndrome and systemic lupus erythematosus. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03463-x] [Reference Citation Analysis]
14 Chinova AA, Zatsepina MN, Ponomareva LA, Popova EN, Moiseev SV. Interstitial lung disease associated with systemic sclerosis in a patient with long-term employment as a marble worker. Sovremennaâ revmatologiâ 2022;16:63-68. [DOI: 10.14412/1996-7012-2022-4-63-68] [Reference Citation Analysis]
15 Skoumalová A, Horák P, Heřmanová Z, Videman J, Smržová A, Palla V. Early diagnosis of systemic scleroderma. Vnitr Lek 2022;68:285-289. [DOI: 10.36290/vnl.2022.061] [Reference Citation Analysis]
16 Assassi S, Shao N, Yin Z, Volkmann ER, Zoz DF, Leonard TB. Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study. Medicine (Baltimore) 2022;101:e29993. [PMID: 35960051 DOI: 10.1097/MD.0000000000029993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kawashima-vasconcelos MY, Santana-gonçalves M, Zanin-silva DC, Malmegrim KCR, Oliveira MC. Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis. Front Immunol 2022;13:941011. [DOI: 10.3389/fimmu.2022.941011] [Reference Citation Analysis]
18 Gul F, Siddiqui A, Srikaram P, Fatima N. Scleroderma and interstitial lung disease - A case report. Annals of Medicine and Surgery 2022;80:104143. [DOI: 10.1016/j.amsu.2022.104143] [Reference Citation Analysis]
19 Molina-Molina M, Castellví I, Valenzuela C, Ramirez J, Rodríguez Portal JA, Franquet T, Narváez J. Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 2022. [PMID: 35912842 DOI: 10.1080/17476348.2022.2107508] [Reference Citation Analysis]
20 Zozaya N, Arrizubieta Basterrechea MI, Bollo E, Castellví I, Espín J, Ortego N, Poveda-Andrés JL, Rodríguez Portal JA, Rivero A, Marcos-Rodríguez JA, Verde L. A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. Int J Technol Assess Health Care 2022;38:e64. [PMID: 35912833 DOI: 10.1017/S0266462322000459] [Reference Citation Analysis]
21 Moriana C, Moulinet T, Jaussaud R, Decker P. JAK inhibitors and systemic sclerosis: A systematic review of the literature. Autoimmunity Reviews 2022. [DOI: 10.1016/j.autrev.2022.103168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. The Lancet Rheumatology 2022;4:e546-55. [DOI: 10.1016/s2665-9913(22)00131-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Broens B, van der Laken CJ, Zwezerijnen GJ, Nossent EJ, Meijboom LJ, Spierings J, de Vries-bouwstra JK, van Laar JM, Voskuyl AE. Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation. Front Immunol 2022;13:923869. [DOI: 10.3389/fimmu.2022.923869] [Reference Citation Analysis]
24 Wu D, Wang W, Li X, Yin B, Ma Y. Single-cell sequencing reveals the antifibrotic effects of YAP/TAZ in systemic sclerosis. Int J Biochem Cell Biol 2022;:106257. [PMID: 35772663 DOI: 10.1016/j.biocel.2022.106257] [Reference Citation Analysis]
25 Bastos AL, Ferreira GA, Mamede M, Mancuzo EV, Teixeira MM, Santos FPST, Ferreira CS, Correa RA. PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease. J Bras Pneumol 2022;48:e20210329. [PMID: 35674522 DOI: 10.36416/1806-3756/e20210329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Lou K, Feng S, Zhang G, Zou J, Zou X. Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. Front Oncol 2022;12:879391. [PMID: 35669417 DOI: 10.3389/fonc.2022.879391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Long Q, Liu Z, Shao Q, Shi H, Huang S, Jiang C, Qian B, Zhong Y, He X, Xiang X, Yang Y, Li B, Yan X, Zhao Q, Wei X, Santos HA, Ye X. Autologous Skin Fibroblast-Based PLGA Nanoparticles for Treating Multiorgan Fibrosis. Adv Sci (Weinh) 2022;:e2200856. [PMID: 35603964 DOI: 10.1002/advs.202200856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ahmed S, Handa R. Management of Connective Tissue Disease-related Interstitial Lung Disease. Curr Pulmonol Rep 2022;:1-13. [PMID: 35530438 DOI: 10.1007/s13665-022-00290-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhang Y, Xu L, Chen Q, Guan T, Lin N, Xu D, Lu L, Dai Q, Song X. Scorpion Venom Polypeptide Inhibits Pulmonary Epithelial-Mesenchymal Transition in Systemic Sclerosis-Interstitial Lung Disease Model Mice by Intervening TGF-β1/Smad Signaling Pathway. Evid Based Complement Alternat Med 2022;2022:6557486. [PMID: 35463079 DOI: 10.1155/2022/6557486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Lillehoj EP, Luzina IG, Atamas SP. Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond. Front Immunol 2022;13:883079. [DOI: 10.3389/fimmu.2022.883079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Case AH. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. Front Med (Lausanne) 2022;9:858339. [PMID: 35372405 DOI: 10.3389/fmed.2022.858339] [Reference Citation Analysis]
32 Tennøe AH, Murbræch K, Didriksen H, Ueland T, Palchevskiy V, Weigt SS, Fretheim H, Midtvedt Ø, Garen T, Brunborg C, Aukrust P, Molberg Ø, Belperio JA, Hoffmann-Vold AM. Serum markers of cardiac complications in a systemic sclerosis cohort. Sci Rep 2022;12:4661. [PMID: 35304587 DOI: 10.1038/s41598-022-08815-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lashari BH, Myers C, Brown J, Galli J, Sehgal S. Recipient selection, timing of referral, and listing for lung transplantation. Indian J Thorac Cardiovasc Surg. [DOI: 10.1007/s12055-022-01330-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Mormile I, Mormile M, Rea G, Petraroli A, Barbieri V, de Paulis A, Rossi FW. Spontaneous Pneumo-Mediastinum in a Post-COVID-19 Patient with Systemic Sclerosis. Healthcare 2022;10:529. [DOI: 10.3390/healthcare10030529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pan Z, Zhu T, Liu Y, Zhang N. Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases. Front Immunol 2022;13:850998. [DOI: 10.3389/fimmu.2022.850998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Knarborg M, Løkke A, Hilberg O, Ibsen R, Sikjær MG. Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population‐based cohort study. Respirology. [DOI: 10.1111/resp.14234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Uegami W, Bychkov A, Ozasa M, Uehara K, Kataoka K, Johkoh T, Kondoh Y, Sakanashi H, Fukuoka J. MIXTURE of human expertise and deep learning-developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease. Mod Pathol 2022. [PMID: 35197560 DOI: 10.1038/s41379-022-01025-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Nagy A, Palmer E, Polivka L, Eszes N, Vincze K, Barczi E, Bohacs A, Tarnoki AD, Tarnoki DL, Nagy G, Kiss E, Maurovich-horvat P, Müller V. Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox. Biomedicines 2022;10:434. [DOI: 10.3390/biomedicines10020434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Mleczko M, Gerkowicz A, Krasowska D. Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review. Int J Mol Sci 2022;23:1767. [PMID: 35163689 DOI: 10.3390/ijms23031767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Panhaleux M, Launay D, Penel N, Lambotte O, Forestier A. The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.01.021] [Reference Citation Analysis]
41 Ikeda S, Yamaguchi Y, Baba T, Sekine A, Ogura T. Letter comments on anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.01.020] [Reference Citation Analysis]
42 Boleto G, Avouac J, Allanore Y. The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2110666. [DOI: 10.1177/1759720x211066686] [Reference Citation Analysis]
43 Wiesendanger M. Scleroderma. Rheumatology for Primary Care Providers 2022. [DOI: 10.1007/978-3-030-80699-6_13] [Reference Citation Analysis]
44 Ding L, Li X, Zhu H, Luo H. Single-Cell Sequencing in Rheumatic Diseases: New Insights from the Perspective of the Cell Type. Aging and disease 2022;13:1633. [DOI: 10.14336/ad.2022.0323] [Reference Citation Analysis]
45 Fu M, Peng D, Lan T, Wei Y, Wei X. Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases. Acta Pharmaceutica Sinica B 2022;12:1740-60. [DOI: 10.1016/j.apsb.2022.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Almalki WH. Introduction to Lung Disease. Microbiome in Inflammatory Lung Diseases 2022. [DOI: 10.1007/978-981-16-8957-4_1] [Reference Citation Analysis]
47 Krawczyk K, Mazur E, Kargol J, Kijowski R, Reich A. The Case of a Patient with Limited Systemic Sclerosis and Interstitial Lung Disease Overlapping with Systemic Lupus Erythematosus. Dermato 2021;1:59-70. [DOI: 10.3390/dermato1020009] [Reference Citation Analysis]
48 Aringer M, Koschel D, Krause A, Schneider U, Gläser S. [Modern drug therapy for systemic sclerosis associated interstitial lung disease]. Dtsch Med Wochenschr 2021. [PMID: 34861699 DOI: 10.1055/a-1658-5176] [Reference Citation Analysis]
49 Hilberg O, Hoffmann-vold A, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, Antoniou KM, Valveny N, Asijee G, Soulard S, Wuyts W. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res 2022;8:00597-2021. [DOI: 10.1183/23120541.00597-2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Zagouras AA, Chatterjee S, Tang WHW. Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00947-w] [Reference Citation Analysis]
51 Ruaro B, Bruni C, Wade B, Baratella E, Confalonieri P, Antonaglia C, Geri P, Biolo M, Confalonieri M, Salton F. Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations With Organ Involvement, Such as Pulmonary Damage? Front Physiol 2021;12:710298. [PMID: 34707506 DOI: 10.3389/fphys.2021.710298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
52 Schmidkonz C. Perspective on Fibroblast Activation Protein-Specific PET/CT in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis-A New Paradigm for Molecular Imaging? J Nucl Med 2022;63:125-6. [PMID: 34649945 DOI: 10.2967/jnumed.121.262944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Sese DGA, Highland KB. Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD): A Distinct Entity and Potential Opportunity. Advances in Pulmonary Hypertension 2021;20:109-118. [DOI: 10.21693/1933-088x-20.4.109] [Reference Citation Analysis]
54 Syed Gaggatur N, Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Sange I. Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. Cureus 2021;13:e17291. [PMID: 34552830 DOI: 10.7759/cureus.17291] [Reference Citation Analysis]
55 Ravanetti F, Ferrini E, Ragionieri L, Khalajzeyqami Z, Nicastro M, Ridwan Y, Kleinjan A, Villetti G, Grandi A, Stellari FF. SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib. Sci Rep 2021;11:18513. [PMID: 34531421 DOI: 10.1038/s41598-021-97728-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
56 Nambiar AM, Walker CM, Sparks JA. Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Ther Adv Respir Dis 2021;15:17534666211039771. [PMID: 34477452 DOI: 10.1177/17534666211039771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
57 Tanguy J, Pommerolle L, Garrido C, Kolb M, Bonniaud P, Goirand F, Bellaye PS. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. Int J Mol Sci 2021;22:9316. [PMID: 34502225 DOI: 10.3390/ijms22179316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
58 Nguyen TTL, Nguyen TYN, Le TK, Nguyen Thanh T, Le TB. Systemic sclerosis-associated interstitial lung disease in a Vietnamese adult female: Case report and literature review. Respirol Case Rep 2021;9:e0827. [PMID: 34401190 DOI: 10.1002/rcr2.827] [Reference Citation Analysis]
59 Luquez-Mindiola A, Atuesta AJ, Gómez-Aldana AJ. Gastrointestinal manifestations of systemic sclerosis: An updated review. World J Clin Cases 2021; 9(22): 6201-6217 [PMID: 34434988 DOI: 10.12998/wjcc.v9.i22.6201] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
60 Uegami W, Bychkov A, Ozasa M, Uehara K, Kataoka K, Johkoh T, Kondo Y, Sakanashi H, Fukuoka J. MIXTURE of human expertise and deep learning—Developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease.. [DOI: 10.1101/2021.07.21.21260920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Simon D, Balogh P, Erdő-Bonyár S, Böröcz K, Minier T, Czirják L, Berki T. Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients. Front Immunol 2021;12:686483. [PMID: 34276673 DOI: 10.3389/fimmu.2021.686483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
62 Allanore Y, Constans J, Godard D, de Pouvourville G, Bouee S, Jeanbat V, Teissier C, Le Lay K, Chollet J, Hachulla E. Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. Journal of Scleroderma and Related Disorders 2022;7:49-56. [DOI: 10.1177/23971983211013979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wu Q, Liu Y, Xie Y, Wei S, Liu Y. Identification of Potential ceRNA Network and Patterns of Immune Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease. Front Cell Dev Biol 2021;9:622021. [PMID: 34222222 DOI: 10.3389/fcell.2021.622021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, Alqalyoobi S, Zeki AA, Leung PS, Shuai Z. Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. Front Immunol 2021;12:684699. [PMID: 34163483 DOI: 10.3389/fimmu.2021.684699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
65 Ma X, Tang R, Luo M, Zeng Z, Shi Y, Tang B, Xiao R. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Clin Rheumatol 2021;40:3185-93. [PMID: 34080081 DOI: 10.1007/s10067-021-05794-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
66 Yılmaz DD, Borekci S, Musellim B. Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. Clin Rheumatol 2021. [PMID: 34056665 DOI: 10.1007/s10067-021-05785-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Castañeda NG, Rubio ER, Emperiale V, Hajkhan AM. Esclerosis sistémica. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1769-1778. [DOI: 10.1016/j.med.2021.04.004] [Reference Citation Analysis]
68 Bergmann C, Distler JHW, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei A, Knitza J, Györfi A, Lück A, Dees C, Soare A, Ramming A, Schönau V, Distler O, Prante O, Ritt P, Götz TI, Köhner M, Cordes M, Bäuerle T, Kuwert T, Schett G, Schmidkonz C. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. The Lancet Rheumatology 2021;3:e185-94. [DOI: 10.1016/s2665-9913(20)30421-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
69 Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 2021;10:2020-8-8. [PMID: 33505480 DOI: 10.7573/dic.2020-8-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Erre GL, Sebastiani M, Manfredi A, Gerratana E, Atzeni F, Passiu G, Mangoni AA. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs Context 2021;10:2020-8-6. [PMID: 33505482 DOI: 10.7573/dic.2020-8-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Ananieva LP, Avdeev SN, Tyurin IЕ, Lila AМ, Zagrebneva AI, Maslyanskiy АL, Terpigorev SA, Stepanyan IV, Lashina EL, Vasilieva OV, Lukina OS, Pershina ES, Klimenko АА, Shostak NA, Nasonov EL. Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. Naučno-praktičeskaâ revmatologiâ 2021;58:631-636. [DOI: 10.47360/1995-4484-2020-631-636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Štorkánová H, Oreská S, Špiritović M, Heřmánková B, Bubová K, Komarc M, Pavelka K, Vencovský J, Distler JHW, Šenolt L, Bečvář R, Tomčík M. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Sci Rep 2021;11:1. [PMID: 33414495 DOI: 10.1038/s41598-020-79139-8] [Cited by in Crossref: 2205] [Cited by in F6Publishing: 2575] [Article Influence: 2205.0] [Reference Citation Analysis]
73 Orlandi M, Landini N, Bruni C, Colagrande S, Matucci-Cerinic M, Kuwana M. Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. J Rheumatol 2021;48:790-2. [PMID: 33262297 DOI: 10.3899/jrheum.200832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Luzina IG, Lillehoj EP, Lockatell V, Hyun SW, Lugkey KN, Imamura A, Ishida H, Cairo CW, Atamas SP, Goldblum SE. Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis. J Pharmacol Exp Ther 2021;376:136-46. [PMID: 33139318 DOI: 10.1124/jpet.120.000223] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
75 Vojinovic T, Cavazzana I, Ceruti P, Fredi M, Modina D, Berlendis M, Franceschini F. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Clin Rev Allergy Immunol 2021;60:87-94. [PMID: 33141387 DOI: 10.1007/s12016-020-08814-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Vonk MC. Is there still a role for cyclophosphamide in the treatment of systemic sclerosis? Journal of Scleroderma and Related Disorders 2021;6:117-22. [DOI: 10.1177/2397198320961673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Del Papa N, Sambataro G, Minniti A, Maglione W, Pignataro F, Caminati A, Harari S, Sambataro D, Vitali C, Caporali RF. Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis. Ther Adv Musculoskelet Dis 2020;12:1759720X20953356. [PMID: 33029203 DOI: 10.1177/1759720X20953356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
78 Ren X, Zhong G, Zhang Q, Zhang L, Sun Y, Zhang Z. Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly. Cell Res 2020;30:763-78. [PMID: 32541867 DOI: 10.1038/s41422-020-0353-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 27.5] [Reference Citation Analysis]
79 Schniering J, Maciukiewicz M, Gabrys HS, Brunner M, Blüthgen C, Meier C, Braga-lagache S, Uldry A, Heller M, Distler O, Guckenberger M, Fretheim H, Hoffmann-vold A, Nakas CT, Frauenfelder T, Tanadini-lang S, Maurer B. Resolving phenotypic and prognostic differences in interstitial lung disease related to systemic sclerosis by computed tomography-based radiomics.. [DOI: 10.1101/2020.06.09.20124800] [Reference Citation Analysis]
80 Del Papa N, Sambataro G, Minniti A, Pignataro F, Caporali R. Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients? Autoimmun Rev 2020;19:102558. [PMID: 32380317 DOI: 10.1016/j.autrev.2020.102558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]